Financial Performance - NeuroPace, Inc. reported a quarterly loss of $0.19 per share, better than the Zacks Consensus Estimate of a loss of $0.26, and an improvement from a loss of $0.28 per share a year ago, representing an earnings surprise of 26.92% [1] - The company posted revenues of $21.06 million for the quarter ended September 2024, exceeding the Zacks Consensus Estimate by 8.95%, and up from $16.43 million in the same quarter last year [2] - Over the last four quarters, NeuroPace has surpassed consensus EPS estimates three times and topped consensus revenue estimates four times [2] Stock Performance - NeuroPace shares have declined approximately 29.4% since the beginning of the year, contrasting with the S&P 500's gain of 25.8% [3] - The current Zacks Rank for NeuroPace is 3 (Hold), indicating that the shares are expected to perform in line with the market in the near future [6] Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is -$0.25 on revenues of $20.54 million, and for the current fiscal year, it is -$1.08 on revenues of $77.25 million [7] - The estimate revisions trend for NeuroPace is mixed, and future changes in estimates will be closely monitored following the recent earnings report [6][7] Industry Context - NeuroPace operates within the Medical - Instruments industry, which is currently ranked in the top 27% of over 250 Zacks industries, suggesting a favorable outlook compared to lower-ranked industries [8] - The performance of NeuroPace's stock may be influenced by the overall outlook for the industry [8]

NeuroPace, Inc. (NPCE) shares rallied 5.1% in the last trading session to close at $6.35. This move can be attributable to notable volume with a higher number of shares being traded than in a typical session. This compares to the stock's 10.1% loss over the past four weeks. NeuroPace recorded a strong price rise on investors' optimism surrounding its impending third-quarter 2024 financial results, which is slated to be released on Nov. 12, 2024, post the closing bell. The Zacks Consensus Estimate for the th ...

MOUNTAIN VIEW, Calif., Oct. 22, 2024 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced it will report financial results for the third quarter of 2024 after market close on Tuesday, November 12, 2024. The company’s management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. Investors interested in listening to the conference call may do so by a ...

Appointed former key developer of RNS System as new Vice President of Research and Development Appointed former head of commercial marketing for Boston Scientific's DBS franchise as the new Vice President of Marketing MOUNTAIN VIEW, Calif., Sept. 04, 2024 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced the appointments of Brett Wingeier as the new Vice President of Research and Development and Kati ...

Company Participation in Conferences - NeuroPace, Inc. will participate in two healthcare investor conferences in September 2024 [1][2] - The first conference is the Lake Street Big8 Best Ideas Growth Conference on September 12th in New York, where management will host one-on-one meetings with investors [2] - The second conference is the Cantor Global Healthcare Conference from September 17th-19th in New York, featuring a fireside chat with CEO Joel Becker and CFO Rebecca Kuhn on September 18th at 11:30am ET [2] Company Overview - NeuroPace is a medical device company based in Mountain View, California, focused on transforming the lives of people living with epilepsy by reducing or eliminating seizures [3] - The company’s RNS System is the first and only commercially available brain-responsive platform that delivers personalized, real-time treatment at the seizure source [3] - This platform aims to improve the standard of care for patients with drug-resistant epilepsy and has potential applications for other brain disorders [3]

MOUNTAIN VIEW, Calif., Aug. 22, 2024 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced it will participate in two healthcare conferences in September. NeuroPace management will host one-on-one meetings with investors at the Wells Fargo 2024 Healthcare Conference, on Wednesday, September 4 in Boston, MA. NeuroPace will also present at the Morgan Stanley 22nd Annual Global Healthcare Conference, which ...

NeuroPace, Inc. (NPCE) reported a second-quarter 2024 loss of 26 cents per share compared with the year-ago quarter's reported loss of 36 cents. The figure was also narrower than the Zacks Consensus Estimate of a loss of 29 cents per share. Q2 Revenues Revenues totaled $19.3 million, up 16.9% year over year. The figure topped the Zacks Consensus Estimate by 2.9%. The revenue growth was driven by increased sales of the RNS System. Margins The gross profit in the reported quarter was $14.1 million, up 18.1% y ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For transition period from to Commission File Number 001-40337 NEUROPACE, INC. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organi ...

NeuroPace Reports First Quarter 2024 Financial Results and Provides Corporate Update Revenue increased to $18.1 million in Q1 2024, a 25% increase over Q1 2023 Extended the maturity date of the Company's term loan by one year to September 30, 2026 Maintained full-year 2024 revenue guidance of $73 to $77 million Management scheduled to host a conference call today at 4:30 p.m. ET Mountain View, Calif. – May 8, 2024 – NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives o ...

nuvei MARCH 5, 2024 Fourth Quarter 2023 Financial Snapshot Q4 2023 | 1 | --- | --- | --- | --- | --- | --- | --- | --- | |------------------------------------------------------------------------|--------------------------------------------------------------|---------------------|--------------------------------------------|--------------------------------------------------------------------------|--------------|--------------------------------------------------------|---------------------| | Total Volume(1) ...